SCHEMBL10992157

SCHEMBL10992157

CC(=O)Nc1ccc(S(=O)(=O)NC(C)=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.73
CA2 P00918 2/20 0.73
MMP1 P03956 1/20 0.73
MMP2 P08253 1/20 0.73
MMP9 P14780 1/20 0.73
MMP8 P22894 1/20 0.73
MMP13 P45452 1/20 0.73
POLB P06746 2/20 0.69
SMN1; SMN2 Q16637 3/20 0.67
DHFR P00374 1/20 0.65
TSHR P16473 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
CA12 O43570 1/20 0.65
CA9 Q16790 1/20 0.65
PKM P14618 2/20 0.61
HTT P42858 1/20 0.61
HSD17B10 Q99714 1/20 0.61
IDO1 P14902 2/20 0.61
F2 P00734 1/20 0.61
PRSS1 P07477 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11590063 0.87 CA1 (0.67) CA1CA2MMP1MMP2MMP9
SCHEMBL14609909 0.85 SMN1; SMN2 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL1102020 0.85 CA1 (0.73) CA1CA2MMP1MMP2MMP9
SCHEMBL8224012 0.85 CA1 (1.00) CA1CA2MMP1MMP2MMP9
SCHEMBL28550935 0.85 CA1 (0.73) CA1CA2MMP1MMP2MMP9
SCHEMBL9887824 0.84 SMN1; SMN2 (0.58) CA1CA2MMP1MMP2MMP9
SCHEMBL11602343 0.84 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL29277108 0.83 TGM2 (0.67) CA1CA2MMP1MMP2MMP9
SCHEMBL5187415 0.83 CA12 (0.76) CA1CA2SMN1; SMN2TSHRCA12
SCHEMBL14420813 0.83 IDO1 (0.62) CA1CA2POLBSMN1; SMN2DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9820997-B2 Pharmaceutical composition for treating disease associated with demyelination of neurons and method of using the pharmaceutical composition SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-11-21 US disclosed
US-9820997-B2 Pharmaceutical composition for treating disease associated with demyelination of neurons and method of using the pharmaceutical composition SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-11-21 US disclosed
CN-105884712-A Compound capable of inhibiting activity of NEDD8 kinase as well as preparation method and pharmaceutical application of compound 中国药科大学 2016-08-24 CN disclosed
US-20160120884-A1 PHARMACEUTICAL COMPOSITION FOR TREATING DISEASE ASSOCIATED WITH DEMYELINATION OF NEURONS AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-05-05 US disclosed
US-20160120884-A1 PHARMACEUTICAL COMPOSITION FOR TREATING DISEASE ASSOCIATED WITH DEMYELINATION OF NEURONS AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-05-05 US disclosed
US-20110197308-A1 Plants Tolerant to HPPD Inhibitor Herbicides BAYER CROPSCIENCE AG (DE) 2011-08-11 US disclosed
US-4495365-A N-Acylsulfonamide herbicidal antidotes STAUFFER CHEMICAL CO. (US) 1985-01-22 US disclosed
US-4347380-A N-Acylsulfonamide herbicidal antidotes STAUFFER CHEMICAL COMPANY (US) 1982-08-31 US disclosed
US-4266078-A N-Acylsulfonamide herbicidal antidotes STAUFFER CHEMICAL COMPANY (US) 1981-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160120884-A1 PHARMACEUTICAL COMPOSITION FOR TREATING DISEASE ASSOCIATED WITH DEMYELINATION OF NEURONS AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION PMP22, MAG, GAP43 CA1 760/4885CA2 3044/4885MMP1 602/4885
US-20110197308-A1 Plants Tolerant to HPPD Inhibitor Herbicides HPD, DDT, PGD CA1 2381/4885CA2 1725/4885MMP1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.